Initial customers have already adopted the system to characterize CTCs for biomarkers such as gene expression, mutations, and chromosomal aberrations.
Designed for high sensitivity enrichment of rare cells including CTCs, stem cells, and immune cells, the IsoFlux System is an automated instrument and microfluidic cartridge.
Fluxion CEO Jeff Jensen said, "We fully expect that the next wave of breakthroughs in cancer diagnostics will come from this group and future customers."
With improved sensitivity of CTC recovery in a low-volume format optimized for analytical platforms, IsoFlux System recovers the tumor cells from a standard blood draw and prepares them for molecular analysis.
Ingham Institute for Applied Medical Research Sydney Dr. Norbert Kienzle said, "Our reconnaissance identified the IsoFlux instrument as a perfectly suitable technology platform for our needs in translational cancer research to analyze circulating tumor cells from patients with various cancer indications."